By: IPP Bureau
Last updated : April 20, 2026 8:02 am
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
Lupin Limited has announced that its US-based subsidiary has entered into a settlement agreement with Humana Inc. regarding an ongoing antitrust litigation in the United States.
The company disclosed in a regulatory filing that its wholly owned arm, Lupin Pharmaceuticals Inc. (LPI), will pay $30 million to resolve claims as part of the broader In Re Generic Pharmaceuticals Antitrust Litigation being heard in Philadelphia.
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal and state antitrust laws related to certain generic pharmaceutical products.
Under the agreement's terms, the settlement provides a full and final release of all claims against LPI and its affiliates, including directors, officers, and employees.
Lupin clarified that its subsidiary denies all allegations, and the agreement implies no admission of liability or unlawful conduct. The company added that it settled to avoid prolonged litigation, associated costs, and uncertainty, particularly as other defendants in the case have also opted for similar resolutions.
Importantly, the company noted that the settlement amount was already provided for in its earlier financial statements, meaning the agreement will not impact current financials.
The development underscores the ongoing legal challenges faced by generic drugmakers in the US market, where antitrust scrutiny has intensified in recent years. For Lupin, the settlement allows the company to draw a line under a key litigation and refocus on its core business operations in a critical market.